An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
This prospective observational study will evaluate the long-term safety of MabThera/Rituxan
 (rituximab) in participants with granulomatosis with polyangiitis (Wegener's) or microscopic
 polyangiitis. Data will be collected for a maximum of 4 years from participants initiated on
 MabThera/Rituxan therapy by their physician according to prescribing information.
Inclusion Criteria:

 -  Adult participants, >/= 18 years of age

 -  Granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), according to
 Chapel Hill Consensus Conference Definitions for MPA and American College of
 Rheumatology (ACR) Criteria for the Classification of GPA

 -  Disease severity requiring rituximab treatment per the investigator's assessment

 Exclusion Criteria:

 -  Prior use of rituximab (except if received within 4 weeks of screening)

 -  Known hypersensitivity to rituximab, to any component of the product, or to murine
 proteins

 -  Pregnant or breastfeeding women

 -  Diagnosis of Churg-Strauss syndrome